TWI566787B - Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b) - Google Patents

Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b) Download PDF

Info

Publication number
TWI566787B
TWI566787B TW104113084A TW104113084A TWI566787B TW I566787 B TWI566787 B TW I566787B TW 104113084 A TW104113084 A TW 104113084A TW 104113084 A TW104113084 A TW 104113084A TW I566787 B TWI566787 B TW I566787B
Authority
TW
Taiwan
Prior art keywords
tablet
core
mass
disintegrating tablet
tegafur
Prior art date
Application number
TW104113084A
Other languages
English (en)
Chinese (zh)
Other versions
TW201529100A (zh
Inventor
岡本拓己
吉澤隆
大西敬人
Original Assignee
大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大鵬藥品工業股份有限公司 filed Critical 大鵬藥品工業股份有限公司
Publication of TW201529100A publication Critical patent/TW201529100A/zh
Application granted granted Critical
Publication of TWI566787B publication Critical patent/TWI566787B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104113084A 2011-05-25 2012-05-24 Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b) TWI566787B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011116884 2011-05-25

Publications (2)

Publication Number Publication Date
TW201529100A TW201529100A (zh) 2015-08-01
TWI566787B true TWI566787B (zh) 2017-01-21

Family

ID=47217314

Family Applications (2)

Application Number Title Priority Date Filing Date
TW101118538A TWI488659B (zh) 2011-05-25 2012-05-24 Containing tegafur, gemcitabine, and otiracazide
TW104113084A TWI566787B (zh) 2011-05-25 2012-05-24 Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW101118538A TWI488659B (zh) 2011-05-25 2012-05-24 Containing tegafur, gemcitabine, and otiracazide

Country Status (16)

Country Link
US (1) US20140335174A1 (enExample)
EP (1) EP2716290B1 (enExample)
JP (2) JP5689173B2 (enExample)
KR (2) KR101869127B1 (enExample)
AU (1) AU2012259803B2 (enExample)
BR (1) BR112013030093B1 (enExample)
CA (1) CA2836865C (enExample)
ES (1) ES2671926T3 (enExample)
IL (1) IL229372B (enExample)
MX (1) MX353289B (enExample)
MY (1) MY167883A (enExample)
PH (1) PH12013502323A1 (enExample)
RU (1) RU2601620C2 (enExample)
SG (2) SG194922A1 (enExample)
TW (2) TWI488659B (enExample)
WO (1) WO2012161240A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194922A1 (en) * 2011-05-25 2013-12-30 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN107837273A (zh) * 2016-09-18 2018-03-27 江苏金甙生物技术有限公司 一种肠溶替吉奥缓释制剂及其制备方法
CN107865871B (zh) * 2016-09-23 2021-09-03 江苏恒瑞医药股份有限公司 一种替吉奥组合物及其制备方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
EP4029380A4 (en) * 2019-09-13 2023-09-13 Meiji Co., Ltd SOLID FOOD AND SOLID MILK
WO2023238929A1 (ja) * 2022-06-10 2023-12-14 大鵬薬品工業株式会社 ピミテスピブを含有する医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015728A1 (en) * 2000-05-18 2002-02-07 Payumo Francis C. Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form
CN1558753A (zh) * 2001-09-28 2004-12-29 ��ʽ�������ͻ�ѧ�о��� 有核型速溶崩解性成型品
CN101711765A (zh) * 2009-10-31 2010-05-26 山东新时代药业有限公司 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654555B2 (en) * 1991-05-27 1994-11-10 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
ATE219658T1 (de) * 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
ZA200403281B (en) * 2001-11-07 2005-12-13 Synthon Bv Tamsulosin tablets.
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
JP4610481B2 (ja) * 2003-03-14 2011-01-12 大鵬薬品工業株式会社 抗腫瘍効果増強剤及び抗腫瘍剤
EP1680092A2 (en) * 2003-09-29 2006-07-19 Cipla Ltd. Pharmaceutical formulation with improved stability
CN100333726C (zh) 2004-12-23 2007-08-29 鲁南制药集团股份有限公司 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片
JP4956423B2 (ja) * 2005-04-01 2012-06-20 大鵬薬品工業株式会社 放射線治療増強剤
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
TWI455732B (zh) * 2007-12-27 2014-10-11 Taiho Pharmaceutical Co Ltd 經口粉粒狀抗腫瘤劑
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
KR100934876B1 (ko) 2008-01-31 2010-01-06 성균관대학교산학협력단 Ｌｉｇａ공정의 도금방법
CN101380327B (zh) * 2008-10-09 2011-01-26 北京恒瑞康达医药科技发展有限公司 抗癌复合缓释组合物及制备
JP5553522B2 (ja) 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
KR20120015318A (ko) * 2009-05-12 2012-02-21 다이호야쿠힌고교 가부시키가이샤 테가푸르?기메라실?오테라실칼륨 배합제 및 옥살리플라틴을 함유하는 항종양제
SG194922A1 (en) * 2011-05-25 2013-12-30 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN102614183B (zh) * 2012-03-05 2013-10-30 齐鲁制药(海南)有限公司 一种替吉奥的口服制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015728A1 (en) * 2000-05-18 2002-02-07 Payumo Francis C. Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form
CN1558753A (zh) * 2001-09-28 2004-12-29 ��ʽ�������ͻ�ѧ�о��� 有核型速溶崩解性成型品
CN101711765A (zh) * 2009-10-31 2010-05-26 山东新时代药业有限公司 一种含有替加氟、吉美嘧啶和奥替拉西钾的分散片

Also Published As

Publication number Publication date
MX353289B (es) 2018-01-05
RU2013157528A (ru) 2015-06-27
KR20170072959A (ko) 2017-06-27
TWI488659B (zh) 2015-06-21
PH12013502323A1 (en) 2014-01-06
MX2013013563A (es) 2013-12-16
KR101869127B1 (ko) 2018-06-19
BR112013030093A2 (pt) 2016-09-20
JP5689173B2 (ja) 2015-03-25
JP2014218523A (ja) 2014-11-20
AU2012259803B2 (en) 2016-03-17
IL229372A0 (en) 2014-01-30
TW201529100A (zh) 2015-08-01
KR20140037879A (ko) 2014-03-27
TW201300141A (zh) 2013-01-01
US20140335174A1 (en) 2014-11-13
CA2836865C (en) 2018-02-27
BR112013030093B1 (pt) 2019-12-10
JPWO2012161240A1 (ja) 2014-07-31
SG194922A1 (en) 2013-12-30
SG10201505503WA (en) 2015-09-29
EP2716290A1 (en) 2014-04-09
NZ617625A (en) 2015-10-30
JP5769853B2 (ja) 2015-08-26
RU2601620C2 (ru) 2016-11-10
CA2836865A1 (en) 2012-11-29
WO2012161240A1 (ja) 2012-11-29
IL229372B (en) 2018-12-31
ES2671926T3 (es) 2018-06-11
EP2716290A4 (en) 2014-11-26
EP2716290B1 (en) 2018-03-14
MY167883A (en) 2018-09-26

Similar Documents

Publication Publication Date Title
CN102387802B (zh) 包含羟考酮和纳洛酮的立即释放药物组合物
TWI556840B (zh) 治療用組成物
CN106943355B (zh) 药物组合物
TWI566787B (zh) Contains tegafur, gemcopyrimidine, otiorasilide potassium tablets (b)
JP5295506B2 (ja) レボフロキサシン含有錠剤
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
CN102895212B (zh) 含有替加氟、吉美拉西、氧嗪酸钾的干压包衣片
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
HK1180584B (en) Dry pressure coated tablet containing tegafur, gimeracil, oteracil potassium
EP3335703A1 (en) Pharmaceutical composition comprising omarigliptin
NZ617625B2 (en) Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
WO2022092767A1 (ko) 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제
JP2022184789A (ja) スルファメトキサゾール及びトリメトプリムを含有する小型錠剤
TW202224681A (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
Swamy Journal of Advanced Pharmaceutical Sciences

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees